ROSN:RUSRosneft Analysis
Data as of 2026-03-12 - not real-time
$0.02
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Rosinbomb (ROSN) is trading at $0.016, well below its 52‑week high of $0.026 and near the computed support of $0.0053. The 20‑day SMA ($0.0232) sits above the 50‑day SMA ($0.0217) and the 200‑day SMA ($0.0135), indicating a bullish price alignment. However, the MACD histogram is negative (‑0.00057) and the signal line is bullish, flagging bearish momentum in the short run. The RSI of 29 places the stock in oversold territory, suggesting a potential rebound if buying interest returns. Trading volume has been decreasing, with today’s volume at 23,000 versus a 3‑month average of over 400,000, underscoring weak liquidity. Volatility is extreme at 156% (30‑day), reflecting wide price swings that can erode capital quickly.
The beta of 0.18 signals low correlation to broader market moves, meaning the stock’s price is driven largely by company‑specific factors. Financial statements show zero revenue, margins, cash or debt, and a trailing EPS of –0.03, indicating no operating history to anchor valuation. The max drawdown of 50% and lack of dividend history further amplify the risk profile. Given the niche focus on solvent‑less extraction presses, regulatory scrutiny in the cannabis‑adjacent space adds a medium regulatory risk. The stock’s market cap of roughly $7.3 million and thin trading suggest high liquidity risk despite its low beta. In this context, the technical upside from the bullish SMA cross and oversold RSI must be weighed against the bearish MACD, minimal fundamentals, and pronounced volatility.
The beta of 0.18 signals low correlation to broader market moves, meaning the stock’s price is driven largely by company‑specific factors. Financial statements show zero revenue, margins, cash or debt, and a trailing EPS of –0.03, indicating no operating history to anchor valuation. The max drawdown of 50% and lack of dividend history further amplify the risk profile. Given the niche focus on solvent‑less extraction presses, regulatory scrutiny in the cannabis‑adjacent space adds a medium regulatory risk. The stock’s market cap of roughly $7.3 million and thin trading suggest high liquidity risk despite its low beta. In this context, the technical upside from the bullish SMA cross and oversold RSI must be weighed against the bearish MACD, minimal fundamentals, and pronounced volatility.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- bearish MACD histogram
- decreasing trading volume
- extremely high short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- bullish SMA crossover
- oversold RSI indicating potential bounce
- low beta reducing market‑wide exposure
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- niche market for solvent‑less extraction equipment
- potential upside if regulatory environment stabilizes
- absence of debt and cash constraints
Key Metrics & Analysis
Financial Health
Industry P/E29.5
Technical Analysis
TrendBullish
RSI29.0
Support$0.01
Resistance$0.03
MA 20$0.02
MA 50$0.02
MA 200$0.01
MACDBearish
VolumeDecreasing
Fear & Greed Index73.59
Valuation
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.18
Volatility156.45%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.